CYTOMEGALOVIRUS INHIBITOR COMPOUNDS

摘要

Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.;

主权项

1. A compound of Formula (I): wherein, n is 1, 2 or 3; m is 1, 2 or 3; R1 is halo, —CN, (C1-6)alkyl, OH, —O—(C1-6)alkyl, (C1-6)haloalkyl or nitro; R2 is H or (C1-6)alkyl optionally substituted with halo, —CN, μ(C3-7)cycloalkyl, —O—(C1-6)alkyl, OH, —NH2, —NH(C1-6)alkyl or —N((C1-6)alkyl)2; R3 is H, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, heterocyclyl, heteroaryl, —(C1-6)alkyl-(C3-7)cycloalkyl, —(C1-6)alkyl-aryl, —(C1-6)alkyl-heterocyclyl or —(C1-6)alkyl-heteroaryl, wherein each said alkyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, either alone or in combination with another radical, is optionally mono-, di-, or tri-substituted with R32; or R2 and R3, together with the N to which they are attached, are linked to form a heterocyclyl or heteroaryl; wherein each said heterocyclyl and heteroaryl are optionally mono-, di-, or tri-substituted with R32; R32 is each independently selected from the group consisting of R33, halo, oxo, —CN, OH, SH, —COOH, —(C1-6)alkyl; —O—(C1-6)alkyl, —S—(C1-6)alkyl, (C3-7)cycloalkyl, (C1-6)haloalkyl, —C(═O)—O—(C1-6)alkyl, —SO2NH2, —SO2—NH(C1-6)alkyl, —SO2—N((C1-6)alkyl)2, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, —C(═O)—NH2, —C(═O)—NH(C1-6)alkyl, —C(═O)—N((C1-6)alkyl)2, —C(═O)—NH—SO2(C1-6)alkyl, —SO2—NH—C(═O)—(C1-6)alkyl, —NH2, —NH(C1-6)alkyl, —N((C1-6)alkyl)2, —NH(C3-7)cycloalkyl, —N((C1-6)alkyl)(C3-7)cycloalkyl, —NH—C(═O)(C1-6)alkyl, —NH—C(═O)O(C1-6)alkyl, heterocyclyl (optionally substituted with (C1-6)alkyl) and heteroaryl (optionally substituted with (C1-6)alkyl); R33 is (C1-6)alkyl optionally mono- or di-substituted with OH, —O—(C1-6)alkyl, —NH2, —NH(C1-6)alkyl or —N((C1-6)alkyl)2; Ring A is heterocyclyl or heteroaryl, wherein Ring A is optionally mono-, di-, or tri-substituted with R4; R4 is each independently selected from the group consisting of halo, oxo, cyano, nitro, (C1-6)alkylidene, R42, —C(═O)—R42, —C(═O)OR42, —OR42, —SR42, —SOR42, —SO2R42, —N(R43)R42, —(C1-6)alkyl-N(R43)R42, —C(═O)—N(R43)R42, —N(R43)—C(═O)R42, —N(R43)—C(═O)O—R42, C(═O)—N(H)—SO2R42, —SO2—N(H)—C(═O)R42, —O—C(═O)—N(R43)R42 and —SO2—N(R43)R42; R42 is each independently selected from the group consisting of H, (C1-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, —(C1-6)alkyl-(C3-7)cycloalkyl, —(C1-6)alkyl-aryl, —(C1-6)alkyl-heterocyclyl, —(C1-6)alkyl-heteroaryl, (C3-7)cycloalkyl, aryl, heterocyclyl and heteroaryl, wherein each said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl and heteroaryl, either alone or in combination with another radical, is optionally substituted with 1 to 3 substituents each independently selected from the group consisting of: halo, cyano, OH, —COOH, —O—(C1-6)alkyl, —S—(C1-6)alkyl, (C3-7)cycloalkyl, —O—(C3-7)cycloalkyl, (C1-6)haloalkyl, —C(═O)—(C1-6)alkyl, —C(═O)—O—(C1-6)alkyl, —SO2NH2, —SO2—NH(C1-6)alkyl, —SO2—N((C1-6)alkyl)2, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, —C(═O)—NH2, —C(═O)—NH(C1-6)alkyl, —C(═O)—N((C1-6)alkyl)2, —C(═O)—N(H)—SO2(C1-6)alkyl, —SO2—N(H)—C(═O)(C1-6)alkyl, —NH2, —NH(C1-6)alkyl, —N((C1-6)alkyl)2, —NH—C(═O)(C1-6)alkyl, —NH—C(═O)—O(C1-6)alkyl and (C1-6)alkyl optionally mono- or di-substituted with OH, —O—(C1-6)alkyl, —S—(C1-6)alkyl, —SO(C1-6)alkyl, —SO2(C1-6)alkyl, heterocyclyl or heteroaryl; R43 is H, (C1-6)haloalkyl or (C1-6)alkyl optionally mono- or di-substituted with OH, —O—(C1-6)alkyl or —O—(C3-7)cycloalkyl; and R5 is H, halo, —CN, (C1-6)alkyl, (C1-6)haloalkyl, —O—(C1-6)alkyl, (C3-7)cycloalkyl, —NH2, —NH(C1-6)alkyl or —N((C1-6)alkyl)2; or a salt thereof.